You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
諾誠健華(9969.HK)漲8% 公佈多項研究數據
格隆匯 06-08 11:18
格隆匯6月8日丨諾誠健華(9969.HK)盤中拉昇一度漲8%報11.6港元。消息面上,諾誠健華奧布替尼治療系統性紅斑狼瘡最新數據在2022 EULAR以重磅口頭報吿發布。奧布替尼治療的SLE患者總體耐受性良好。在所有可評估的患者中,口服奧布替尼50毫克、80毫克和100毫克治療的患者在第12周SLE反應指數-4(SRI-4)的應答率分別為50.0%(7/14)、61.5%(8/13)和64.3%(9/14),而服用安慰劑的患者SRI-4應答率為35.7%(5/14),這表明療效呈劑量依賴性的改善趨勢。另外,諾誠健華多項腫瘤管線最新數據在2022年美國臨牀腫瘤學會(ASCO)年會上進行了公佈。高選擇性的不可逆FGFR 1-4抑制劑gunagratinib(ICP-192)治療FGF/FGFR 基因改變的頭頸癌患者的臨牀I期數據顯示,gunagratinib在FGF/FGFR基因異常的頭頸癌患者中具有抗腫瘤活性。該研究在包括頭頸癌在內的晚期實體瘤患者中,gunagratinib的安全性和耐受性均表現良好。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account